
Bladder pills long suspected of harming memory did no worse than the newer alternative
- Observational study
- 830,393 adults newly treated for overactive bladder
For years, a family of overactive bladder pills has carried a dementia warning. A study of more than 830,000 people found the newer alternative was not linked to less dementia. The small gap that did appear leaned the other way.
The older drugs, called anticholinergics, include oxybutynin. Doctors have increasingly switched patients to a newer class, beta-3 agonists such as mirabegron. The researchers searched Epic Cosmos, a large pool of electronic health records. They identified 830,393 adults aged 40 to 90 who started treatment for overactive bladder between 2012 and 2025 and had no dementia at the start. Most, 572,489, began on an anticholinergic the team classed as high-risk. Another 49,592 began on a lower-risk one, and 208,312 on a beta-3 agonist. Over the follow-up, 65,134 were diagnosed with dementia.
People who get different drugs often differ in other ways, so the team weighted the groups to make them more comparable. Estimated 10-year dementia rates came out at 20.0% for the newer drugs, 19.0% for the lower-risk older drugs and 18.1% for the high-risk ones. The high-risk group's slightly lower risk was statistically clear. The lower-risk group did not differ from the newer drugs.
The authors don't take this as evidence that the older pills protect the brain. Their likelier explanation is who gets prescribed what. If doctors steer patients they already worry about toward the newer drug, that group will show more dementia whatever the pill does. Researchers call this confounding by indication.
They also checked how fragile the result is with E-values, which estimate how strong a hidden factor would need to be to erase a finding. The values were 1.29 and 1.20. Modest unmeasured confounding could explain the differences.
The records showed prescriptions ordered, not pills taken, and doses were mostly missing. Dementia came from diagnosis codes or dementia medications, which can miss early disease. Subgroup results were inconsistent.
The study does not show the older drugs are safe for the brain. It does undercut the expectation that switching to the newer class lowers dementia risk.
Get the next issue by email
Our weekly newsletter on what is new in health research, explained for curious readers and linked to the original studies. One email a week.
Sources
Source titles are preserved as published.
Reference Range Weekly is for general information. It does not provide medical advice, diagnosis, or treatment.